We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Read MoreHide Full Article
Key Takeaways
Sanofi reported Q1 earnings and sales above estimates, with double-digit growth at CER.
Dupixent led growth with sales rising 30.8% year over year, driven by strong global demand.
New drugs like Altuviiio and Ayvakit, plus vaccines, boosted overall revenue growth.
Sanofi (SNY - Free Report) reported first-quarter 2026 adjusted earnings of $1.10 per American depositary share, which beat the Zacks Consensus Estimate of $1.06 per share. Earnings of €1.88 per share rose 5% on a reported basis and 14.0% on a constant currency rate (“CER”) basis, driven by cost control.
Net sales rose 6.2% on a reported basis to $12.3 billion (€10.51 billion). Sales rose 13.6% on a CER basis. Sales beat the Zacks Consensus Estimate of $11.99 billion.
Sales rose 26.2% at CER in the United States, 0.2% in the Rest of the World (including China, Japan, Brazil and Russia) and 5.9% in Europe.
All growth rates mentioned below are on a year-on-year basis and at CER.
SNY’s Dupixent Continues to Outperform
In Immunology, blockbuster drug Dupixent generated sales of €4.17 billion in the quarter, up 30.8% year over year, driven by strong prescription trends across all approved indications and geographies.
Sales of the drug in the United States rose 35.9%. Dupixent sales rose 22.4% in Europe and 14.9% in the Rest of the World.
Sanofi markets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
SNY’s Rare Disease Drugs’ Performance
Among Sanofi’s rare disease drugs, the rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €325 million in the first quarter, up 42.2% year over year, mainly driven by patient switches in the U.S. hemophilia A market and launch in Japan and Taiwan. As much as 83% of Altuviiio’s sales were in the United States.
Among the rare disease drugs in the Pompe franchise, Nexviazyme/Nexviadzyme recorded sales of €208 million, up 13.3% year over year, mainly driven by strong sales growth in Europe. Myozyme sales declined 13.3% year over year to €112 million due to patients switching to Nexviazyme. Fabrazyme sales were €265 million, up 7.6% year over year. In the Gaucher franchise, Cerezyme sales rose 1.1% year over year to €186 million.
Cablivi recorded sales of €68 million, up 9% year over year, driven by patient growth in the United States and Europe.
Among the rare blood disorder drugs, Eloctate sales declined 7.1% to €58 million in the quarter due to patients switching to the new drug Altuviiio.
Xenpozyme recorded sales of €63 million in the quarter, up 17.9% year over year.
New drug Qfitlia (fitusiran) generated €5 million in sales, compared with €4 million in the previous quarter.
Another new drug, Wayrilz (rilzabrutinib) generated €10 million in sales in the first quarter versus €6 million in the previous quarter.
Ayvakit, added from last year’s acquisition of Blueprint Medicines, recorded sales of €177 million compared with €168 million in the previous quarter, driven by continued patient growth. Higher government rebates hurt U.S. sales to an extent.
SNY’s Oncology & Other Drugs
In Oncology, Sarclisa sales rose 30.1% year over year to €167 million, driven by increased use in earlier lines of treatment in Europe and strong growth from Rest of World.
In Others, Toujeo recorded sales of €375.0 million, up 10.5% year over year, driven mainly by volume growth and market share gains in the United States and Europe. Lantus sales declined 0.7% to €419 million. Rezurock recorded sales of €133 million, up 11.5% year over year. Tzield sales were €14 million in the quarter, up 36.4% year over year, driven mainly by U.S. sales.
Plavix sales declined 3.3% to €224 million. Lovenox sales decreased 22.3% to €184 million.
Heplisav-B Added from Dynavax Deal Boosts SNY’s Vaccine Sales
Total vaccine sales rose 2.1% to €1.29 billion, mainly due to higher sales of Sanofi and partner AstraZeneca’s (AZN - Free Report) respiratory syncytial virus or RSV antibody, Beyfortusand Polio/Pertussis/Hib (PPH) vaccines.
Sales of PPH vaccines rose 4.2% year over year to €664 million, gaining from the inclusion of the newly acquired adult hepatitis B vaccine, Heplisav-B, from the acquisition of Dynavax, which closed in February. Sales of meningitis, travel and other endemic vaccines declined 2.0% year over year to €278 million in the quarter. Sales of flu vaccines declined 4.1% year over year to €67 million.
AstraZeneca-partnered Beyfortus recorded sales of €284 million in the quarter, up 2.8% year over year. Gains from expanded geographical availability in Europe and Rest of the World were partially offset by softer sales in the United States due to a tough comparison from inventory increase in the year-ago quarter.
SNY Maintains 2026 Guidance
Sanofi maintained its previously issued financial outlook for 2026.
Sanofi expects sales to rise by a high single-digit percentage at CER. Sanofi expects earnings to grow faster than sales in 2026 at CER, before the impact of share repurchases.
Our Take on SNY’s Q1 Results
Sanofi’s first-quarter results were strong as it beat estimates for earnings as well as sales. Both sales and earnings rose in a double-digit range at CER in the quarter. Higher sales of Dupixent and contributions from new products like Altuviiio and Ayvakit drove top-line growth. Vaccine sales also improved in the quarter, benefiting from the inclusion of Heplisav-B. Dupixent continues to be the key top-line driver with global sales rising above €4 billion for the past three consecutive quarters.
Sanofi’s shares were up more than 4% in pre-market trading in response. Sanofi’s stock has declined 12.4% in the past year against the industry’s increase of 12.9%.
Image Source: Zacks Investment Research
Sanofi is seeing a good uptake of its new medicines and vaccines. Altuviiio achieved blockbuster sales in 2025 and Ayvakit is expected to become the next blockbuster drug in 2026. Last year, Sanofi launched Qfitlia and Wayrilz. Sales of Sanofi’s newly launched drugs and vaccines rose almost 50% in the first quarter.
Some potential blockbuster assets in phase III development are amlitelimab (anti-OX40L mAb for moderate-to-severe atopic dermatitis) and frexalimab (anti-CD40L mAb for multiple sclerosis). Regulatory applications for amlitelimab and frexalimab are planned in the second half of 2026 and 2027, respectively.
Sanofi has also been active on the M&A front. In February, it completed the previously announced acquisition of vaccine maker Dynavax Technologies for a total equity value of approximately $2.2 billion. Last year, it acquired Blueprint Medicines, which has expanded its presence in rare immunological diseases and Vigil Neuroscience, which expanded its early-stage pipeline in neurology. The company has also got a new chief executive officer, Belén Garijo, who will replace Paul Hudson, effective April 29, 2026.
View the Zacks #1 Rank List
Image: Bigstock
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Key Takeaways
Sanofi (SNY - Free Report) reported first-quarter 2026 adjusted earnings of $1.10 per American depositary share, which beat the Zacks Consensus Estimate of $1.06 per share. Earnings of €1.88 per share rose 5% on a reported basis and 14.0% on a constant currency rate (“CER”) basis, driven by cost control.
Net sales rose 6.2% on a reported basis to $12.3 billion (€10.51 billion). Sales rose 13.6% on a CER basis. Sales beat the Zacks Consensus Estimate of $11.99 billion.
Sales rose 26.2% at CER in the United States, 0.2% in the Rest of the World (including China, Japan, Brazil and Russia) and 5.9% in Europe.
All growth rates mentioned below are on a year-on-year basis and at CER.
SNY’s Dupixent Continues to Outperform
In Immunology, blockbuster drug Dupixent generated sales of €4.17 billion in the quarter, up 30.8% year over year, driven by strong prescription trends across all approved indications and geographies.
Sales of the drug in the United States rose 35.9%. Dupixent sales rose 22.4% in Europe and 14.9% in the Rest of the World.
Sanofi markets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
SNY’s Rare Disease Drugs’ Performance
Among Sanofi’s rare disease drugs, the rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €325 million in the first quarter, up 42.2% year over year, mainly driven by patient switches in the U.S. hemophilia A market and launch in Japan and Taiwan. As much as 83% of Altuviiio’s sales were in the United States.
Among the rare disease drugs in the Pompe franchise, Nexviazyme/Nexviadzyme recorded sales of €208 million, up 13.3% year over year, mainly driven by strong sales growth in Europe. Myozyme sales declined 13.3% year over year to €112 million due to patients switching to Nexviazyme. Fabrazyme sales were €265 million, up 7.6% year over year. In the Gaucher franchise, Cerezyme sales rose 1.1% year over year to €186 million.
Cablivi recorded sales of €68 million, up 9% year over year, driven by patient growth in the United States and Europe.
Among the rare blood disorder drugs, Eloctate sales declined 7.1% to €58 million in the quarter due to patients switching to the new drug Altuviiio.
Xenpozyme recorded sales of €63 million in the quarter, up 17.9% year over year.
New drug Qfitlia (fitusiran) generated €5 million in sales, compared with €4 million in the previous quarter.
Another new drug, Wayrilz (rilzabrutinib) generated €10 million in sales in the first quarter versus €6 million in the previous quarter.
Ayvakit, added from last year’s acquisition of Blueprint Medicines, recorded sales of €177 million compared with €168 million in the previous quarter, driven by continued patient growth. Higher government rebates hurt U.S. sales to an extent.
SNY’s Oncology & Other Drugs
In Oncology, Sarclisa sales rose 30.1% year over year to €167 million, driven by increased use in earlier lines of treatment in Europe and strong growth from Rest of World.
In Others, Toujeo recorded sales of €375.0 million, up 10.5% year over year, driven mainly by volume growth and market share gains in the United States and Europe. Lantus sales declined 0.7% to €419 million. Rezurock recorded sales of €133 million, up 11.5% year over year. Tzield sales were €14 million in the quarter, up 36.4% year over year, driven mainly by U.S. sales.
Plavix sales declined 3.3% to €224 million. Lovenox sales decreased 22.3% to €184 million.
Heplisav-B Added from Dynavax Deal Boosts SNY’s Vaccine Sales
Total vaccine sales rose 2.1% to €1.29 billion, mainly due to higher sales of Sanofi and partner AstraZeneca’s (AZN - Free Report) respiratory syncytial virus or RSV antibody, Beyfortusand Polio/Pertussis/Hib (PPH) vaccines.
Sales of PPH vaccines rose 4.2% year over year to €664 million, gaining from the inclusion of the newly acquired adult hepatitis B vaccine, Heplisav-B, from the acquisition of Dynavax, which closed in February. Sales of meningitis, travel and other endemic vaccines declined 2.0% year over year to €278 million in the quarter. Sales of flu vaccines declined 4.1% year over year to €67 million.
AstraZeneca-partnered Beyfortus recorded sales of €284 million in the quarter, up 2.8% year over year. Gains from expanded geographical availability in Europe and Rest of the World were partially offset by softer sales in the United States due to a tough comparison from inventory increase in the year-ago quarter.
SNY Maintains 2026 Guidance
Sanofi maintained its previously issued financial outlook for 2026.
Sanofi expects sales to rise by a high single-digit percentage at CER. Sanofi expects earnings to grow faster than sales in 2026 at CER, before the impact of share repurchases.
Our Take on SNY’s Q1 Results
Sanofi’s first-quarter results were strong as it beat estimates for earnings as well as sales. Both sales and earnings rose in a double-digit range at CER in the quarter. Higher sales of Dupixent and contributions from new products like Altuviiio and Ayvakit drove top-line growth. Vaccine sales also improved in the quarter, benefiting from the inclusion of Heplisav-B. Dupixent continues to be the key top-line driver with global sales rising above €4 billion for the past three consecutive quarters.
Sanofi’s shares were up more than 4% in pre-market trading in response. Sanofi’s stock has declined 12.4% in the past year against the industry’s increase of 12.9%.
Image Source: Zacks Investment Research
Sanofi is seeing a good uptake of its new medicines and vaccines. Altuviiio achieved blockbuster sales in 2025 and Ayvakit is expected to become the next blockbuster drug in 2026. Last year, Sanofi launched Qfitlia and Wayrilz. Sales of Sanofi’s newly launched drugs and vaccines rose almost 50% in the first quarter.
Some potential blockbuster assets in phase III development are amlitelimab (anti-OX40L mAb for moderate-to-severe atopic dermatitis) and frexalimab (anti-CD40L mAb for multiple sclerosis). Regulatory applications for amlitelimab and frexalimab are planned in the second half of 2026 and 2027, respectively.
Sanofi has also been active on the M&A front. In February, it completed the previously announced acquisition of vaccine maker Dynavax Technologies for a total equity value of approximately $2.2 billion. Last year, it acquired Blueprint Medicines, which has expanded its presence in rare immunological diseases and Vigil Neuroscience, which expanded its early-stage pipeline in neurology. The company has also got a new chief executive officer, Belén Garijo, who will replace Paul Hudson, effective April 29, 2026.
SNY’s Zacks Rank
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sanofi Price and Consensus
Sanofi price-consensus-chart | Sanofi Quote